A Study in Participants With Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 417 participants.

Also called NCT01113801

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 417 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01113801
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Czechia, France, Hungary, Israel, Puerto Rico (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01113801. Randomized; triple masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2017-12-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study in Participants With Diabetic Kidney Disease
Condition
Diabetic Kidney Disease
Condition
Diabetic Nephropathy
Condition
Diabetic Glomerulosclerosis
Intervention (Drug)
LY2382770
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01113801
Content hash
5c558504c48e964d49dd729d7d00503cf697c9757c6f3629d93c63c42ab4b1d3